Harris & Harris Group, Inc., has always been involved with founding, incubating and building transformative companies from disruptive science. In fact in the vast majority of the companies we have invested in since our founding, we have been the first institutional investor or syndicate of first institutional investor in these companies.
We have demonstrated that we have the ability to discover, diligence, invest, build and realize gains in transformative companies built from these emerging areas of science.
In 2002, we focused our efforts investing in companies that were enabled at the nanoscale. Nanotechnology can be considered a set of tools that is applicable to a broad set of industries. Hence, the market opportunity for nanotechnology-enabled solutions continues to be large, diverse and growing.
Many of the disruptive scientific breakthroughs that are the basis of the transformative companies we build occur at the nanoscale. This focus permitted Harris & Harris Group to become a leader investing in this emerging space. Recent exits in companies such as BioVex Group, Inc., Solazyme, Inc., Crystal-IS, Inc. and Xradia, Inc. attest to our leadership position. Additionally, our interdisciplinary scientific backgrounds led us to identify interesting breakthroughs that were occurring ever more often at the intersection of different scientific disciplines.
In 2009, we began to focus more of our efforts on building companies resulting from scientific breakthroughs occurring at the intersection of different sciences combined with biology. Our team, with scientific backgrounds in chemistry, biochemical engineering, physics, genetics and material science, is uniquely qualified to identify, diligence and invest in the intersection of biology with these other disciplines.
BIOLOGY+ became our distinctive approach to building high value life science companies.
We define our investment focus of BIOLOGY+ as investments in interdisciplinary life science companies where biology innovation is intersecting with innovations in areas such as electronics, physics, materials science, chemistry, information technology, engineering and mathematics. We focus on this intersection because we believe interdisciplinary innovation will be required in order to address many of the life science challenges of the future.
Currently, we plan to focus all our efforts on building new companies enabled by our BIOLOGY+ thesis. We believe areas such as personalized genomics, novel therapeutics for cancer, and 3D non-invasive imaging and diagnostics, as well applications in agriculture, industrial biotechnology, water, functional foods and personal health will all be influenced by innovations in BIOLOGY+.